

Sairah Ahmed

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1102132/publications.pdf>

Version: 2024-02-01

137
papers

3,822
citations

136940

32
h-index

155644

55
g-index

139
all docs

139
docs citations

139
times ranked

4940
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 clinical trial using mblL21 ex vivo "expanded donor-derived NK cells after haploidentical transplantation. <i>Blood</i> , 2017, 130, 1857-1868.	1.4	256
2	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen "Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
3	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	2.5	158
4	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
5	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 2871-2883.	5.2	134
6	Allogeneic BK Virus "Specific T Cells for Progressive Multifocal Leukoencephalopathy. <i>New England Journal of Medicine</i> , 2018, 379, 1443-1451.	27.0	130
7	Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. <i>Blood</i> , 2015, 125, 2885-2892.	1.4	118
8	Clinical efficacy of anakinra to mitigate CAR T-cell therapy "associated toxicity in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3123-3127.	5.2	115
9	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.8	110
10	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
11	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 3272-3276.	1.4	95
12	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	3.5	92
13	Results of a 2 "arm, phase 2 clinical trial using post "transplantation cyclophosphamide for the prevention of graft "versus "host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	4.1	75
14	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3943-3951.	5.2	69
15	Prognostic Factors of Hepatosplenic T-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 676-688.	3.7	65
16	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1232-1236.	2.0	64
17	Post "transplantation cyclophosphamide versus conventional graft "versus "host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	2.5	61
18	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61

#	ARTICLE	IF	CITATIONS
19	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
20	CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. <i>Blood Advances</i> , 2021, 5, 2799-2806.	5.2	57
21	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
22	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 110-117.	3.5	54
23	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 113-121.	0.8	50
24	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	4.1	48
25	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1618-1625.	2.0	46
26	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
27	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	7.1	39
28	Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 493-498.	2.0	38
29	BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. <i>Blood</i> , 2014, 124, 2306-2312.	1.4	35
30	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
31	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
32	Safety of CAR T-cell therapy in kidney transplant recipients. <i>Blood</i> , 2021, 137, 2558-2562.	1.4	33
33	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	3.5	32
34	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32
35	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. <i>Oncotarget</i> , 2018, 9, 35611-35622.	1.8	31
36	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	17.0	29

#	ARTICLE	IF	CITATIONS
37	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 971-971.	1.4	29
38	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	5.0	29
39	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 472-476.	0.4	28
40	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	5.2	27
41	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
42	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
43	Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2867-2871.	5.2	24
44	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	4.6	23
45	Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 765-765.	1.4	23
46	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. <i>Blood Advances</i> , 2019, 3, 1661-1669.	5.2	21
47	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	1.2	21
48	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
49	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	17.0	20
50	Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1079-1087.	2.0	20
51	Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e474-e478.	4.6	20
52	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. <i>Blood Advances</i> , 2020, 4, 47-54.	5.2	20
53	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	4.6	19
54	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19

#	ARTICLE	IF	CITATIONS
55	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	2.8	19
56	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	2.4	19
57	Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. <i>Blood</i> , 2022, 140, 504-515.	1.4	19
58	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	2.2	18
59	Poor immune reconstitution is associated with symptomatic <scp>BK</scp> polyomavirus viremia in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12632.	1.7	18
60	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 959-967.	1.6	18
61	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	1.2	18
62	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 560-569.	0.4	17
63	Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. <i>Cancer</i> , 2020, 126, 2183-2192.	4.1	17
64	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
65	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018, 131, 1248-1257.	1.4	16
66	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
67	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
68	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.8	15
69	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1717-1725.	2.5	15
70	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <i>Cancer</i> , 2017, 123, 2661-2670.	4.1	14
71	Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications. <i>Leukemia and Lymphoma</i> , 2010, 51, 1163-1177.	1.3	13
72	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017, 123, 3367-3376.	4.1	13

#	ARTICLE	IF	CITATIONS
73	Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).. Journal of Clinical Oncology, 2020, 38, 8011-8011.	1.6	13
74	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Seminars in Oncology Nursing, 2021, 37, 151216.	1.5	13
75	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	1.2	13
76	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 122-128.	0.4	12
77	Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 2304-2311.	7.0	11
78	Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, 1094-1098.	2.0	11
79	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥ 75 years. Leukemia and Lymphoma, 2019, 60, 3536-3543.	1.3	11
80	Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1637-1641.	2.0	11
81	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clinical Cancer Research, 2019, 25, 6781-6787.	7.0	10
82	Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 939-944.	4.9	9
83	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 78-85.	2.0	9
84	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Advances in Radiation Oncology, 2018, 3, 639-646.	1.2	9
85	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. British Journal of Haematology, 2021, 192, 560-567.	2.5	9
86	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica, 2022, 107, 899-908.	3.5	9
87	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	1.4	9
88	Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood, 2017, 129, 3031-3033.	1.4	8
89	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Network Open, 2020, 3, e2013935.	5.9	8
90	Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 999-1001.	2.4	7

#	ARTICLE	IF	CITATIONS
91	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.4	7
92	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	5.2	7
93	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
94	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	1.6	6
95	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	3.5	6
96	Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 32-39.	2.3	6
97	Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. <i>Blood Advances</i> , 2022, 6, 2267-2274.	5.2	6
98	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
99	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6
100	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1405-1410.	2.0	5
101	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	4.1	5
102	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. <i>Cancer Epidemiology</i> , 2021, 75, 102044.	1.9	5
103	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	1.4	5
104	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	1.4	5
105	A review of pathobiology and therapies for classic Hodgkin lymphoma. <i>Blood Reviews</i> , 2022, 55, 100949.	5.7	5
106	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016, 128, 3554-3554.	1.4	4
107	Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes. <i>Journal of Personalized Medicine</i> , 2022, 12, 125.	2.5	4
108	Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2015, 5, 29.	2.8	3

#	ARTICLE	IF	CITATIONS
109	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
110	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	1.2	3
111	Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. <i>Blood</i> , 2014, 124, 1245-1245.	1.4	3
112	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	3
113	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.4	2
114	Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. <i>Blood</i> , 2013, 122, 541-541.	1.4	2
115	Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. <i>Blood</i> , 2014, 124, 3859-3859.	1.4	2
116	CAR-T in B-cell lymphomas: the past, present and future. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.4	2
117	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
118	Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S33-S34.	2.0	1
119	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	1.2	1
120	Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
121	Increased Incidence of Human Papillomavirus-Related Precancer or Second Malignancy Among Allogeneic Stem Cell Transplantation Patients: A SEER-Medicare Population Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1016.e1-1016.e9.	1.2	1
122	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011, 118, 333-333.	1.4	1
123	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5884-5884.	1.4	1
124	PX-478, a Novel Small Molecule Inhibitor of Hypoxia Inducible Factor-1 (HIF-1) Downregulates HIF and Induces Cytotoxicity in Diffuse Large B Cell Lymphoma Cells.. <i>Blood</i> , 2009, 114, 2713-2713.	1.4	1
125	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. <i>Blood</i> , 2012, 120, 3129-3129.	1.4	1
126	Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2021, 29, 97-105.	2.2	0

#	ARTICLE	IF	CITATIONS
127	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. <i>Blood</i> , 2011, 118, 3106-3106.	1.4	0
128	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7010-7010.	1.6	0
129	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). <i>Blood</i> , 2013, 122, 2142-2142.	1.4	0
130	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8601-8601.	1.6	0
131	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 2276-2276.	1.4	0
132	Haploidentical Donors in Addition to Transplantation in Chronic Phase Associate with Improved Gvhd-Free Relapse-Free Survival (GRFS) for Patients with Advanced CML. <i>Blood</i> , 2016, 128, 4583-4583.	1.4	0
133	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 4667-4667.	1.4	0
134	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	1.4	0
135	Hematopoietic Stem Cell Transplantation for Hodgkin Lymphoma. , 2019, , 231-243.		0
136	Outcomes in Advanced-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2021, 138, 2519-2519.	1.4	0
137	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 264.e1-264.e9.	1.2	0